10X Genomics is a technology company.
10X Genomics is a technology company.
10X Genomics has raised $216.0M across 4 funding rounds.
10X Genomics has raised $216.0M in total across 4 funding rounds.
10X Genomics has raised $216.0M in total across 4 funding rounds.
10X Genomics's investors include Andreessen Horowitz, Bessemer Venture Partners, Meritech Capital Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams, Greylock, Harrison Metal, Venrock, Brad Garlinghouse.
10x Genomics is a life science technology company that develops innovative instruments, reagents, and software for single-cell, spatial, and in situ analysis to accelerate mastery of biology and advance human health.[1][2][3] It serves academic researchers, pharmaceutical companies, and biotech firms by providing high-resolution tools that enable breakthroughs in oncology, immunology, neuroscience, and drug development, with products cited in over 10,000 publications and adopted by 97 of the top 100 global research institutions.[1][3][5] The company has placed over 4,600 instruments worldwide, holds 1,750+ patents, and continues strong growth through launches like GEM-X Flex for high-scale single-cell profiling and Xenium Protein for spatial multiomics.[1][3][6]
Founded in 2012, 10x Genomics emerged from founders' efforts to overcome limitations in existing genomics tools, focusing on high-throughput single-cell and spatial analysis for complex biological insights.[6] The company quickly gained traction with the 2015 launch of its Chromium System, revolutionizing single-cell library preparation at low cost and high scale.[6] Pivotal expansions included spatial biology platforms like Visium for tissue gene mapping and Xenium for in situ analysis, earning Top 10 Innovations awards from The Scientist in 2015, 2017-2021.[1][6] By 2024-2025, it introduced GEM-X, Visium HD, Xenium Prime, and a roadmap for plate-based workflows and multiomics, targeting 50% sales from biopharma by mid-2025.[6]
10x Genomics rides the spatial biology and multiomics wave, where understanding gene expression in tissue context is transforming drug discovery amid rising failures (90% of candidates flop).[3][6] Timing aligns with AI-driven biology, providing high-quality single-cell data for virtual cell models and therapies like melanoma cell treatments.[3] Market forces favor it: booming biopharma demand (aiming for 50% revenue), genomics market growth, and need for scalable tools beyond traditional methods.[5][6] It influences the ecosystem by empowering 97% of top institutions and pharma, accelerating discoveries in cancer, autoimmune diseases, and beyond, while expanding from research to clinical applications.[1][2][7]
10x Genomics is poised for expansion with its 2025 roadmap, including Chromium mega-scale enhancements, Visium upgrades, and Xenium protein analysis for fuller multiomics.[6] Trends like AI-biology integration, biopharma shift, and spatial tech maturation will propel growth, potentially evolving from research tools to direct clinical impact.[3][6][7] As it masters biology's complexity, 10x continues fueling exponential progress in human health through reliable, breakthrough-enabling innovations.[1][2]
10X Genomics has raised $216.0M across 4 funding rounds. Most recently, it raised $35.0M Series D in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $35.0M Series D | Andreessen Horowitz, Bessemer Venture Partners, Meritech Capital Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams | |
| Apr 1, 2018 | $50.0M Series D | Andreessen Horowitz, Bessemer Venture Partners, Meritech Capital Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams | |
| Feb 1, 2016 | $75.0M Series C | Greylock, Harrison Metal, Venrock, Brad Garlinghouse | |
| Dec 1, 2014 | $56.0M Series B | Greylock, Harrison Metal, Venrock, Brad Garlinghouse |